Winslow Evans & Crocker’s Repligen RGEN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q4
$1.06M Buy
5,558
+575
+12% +$105K 0.2% 119
2020
Q3
$735K Buy
4,983
+200
+4% +$28.6K 0.18% 125
2020
Q2
$591K Buy
4,783
+757
+19% +$89.1K 0.16% 136
2020
Q1
$390K Buy
4,026
+3,992
+11,741% +$385K 0.13% 158
2019
Q4
$4K Hold
34
﹤0.01% 1017
2019
Q3
$4K Buy
+34
New +$2.97K ﹤0.01% 1008

Other funds holding RGEN

Winslow Evans & Crocker's RGEN Position: Q4 2020 in Review

Winslow Evans & Crocker increased its Repligen (RGEN) stake by 12% in Q4 2020, buying an estimated $105K and bringing the position to 5,558 shares worth $1.06M. The position accounts for 0.2% of the portfolio, ranked #119.

Winslow Evans & Crocker first reported a position in RGEN in Q3 2019 and has held it in 6 quarters since. 449 funds tracked by Wall St. Rank hold RGEN as of Q4 2020.

  • Winslow Evans & Crocker held 5,558 shares of Repligen worth $1.06M as of Q4 2020.
  • Winslow Evans & Crocker bought 575 Repligen shares in Q4 2020, an estimated $105K.
  • Repligen made up 0.2% of Winslow Evans & Crocker's portfolio in Q4 2020, its #119 holding.
  • Winslow Evans & Crocker first reported a position in Repligen in Q3 2019 and has held it in 6 quarters since.
  • 449 funds tracked by Wall St. Rank held Repligen as of Q4 2020.

Based on Winslow Evans & Crocker's 13F filing for Q4 2020, filed 3 Feb 2021.